Accounting for nearly 90% of all pancreatic cancers, pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of just 13%. Late-stage diagnosis, limited surgical options, and toxic chemotherapy regimens contribute to its poor outcomes.